Positions

Overview

  • Dr. Standaert was named the John N. Whitaker Professor & Chair of Neurology in 2012. Prior to that, he was appointed the John T. and Juanelle D. Strain Endowed Chair by the Board of Trustees of the University of Alabama system, which he held for five years. He received his M.D. and Ph.D. degrees from Washington University in St. Louis in medicine and pharmacology in 1988. He completed a one-year internship in medicine at Jewish Hospital of St. Louis in 1989 and a three-year neurology residency in 1992 at the University of Pennsylvania. He completed a three-year research and clinical fellowship in neurology (movement disorders) at Harvard Medical School Massachusetts General Hospital in 1995. Dr. Standaert is licensed to practice medicine in the states of Massachusetts and Alabama and was board certified in 1993 by the American Board of Psychiatry and Neurology. Dr. Standaert's clinical teaching has consisted of: serving as an attending physician on the MGH Neurology inpatient service, one month each year; teaching residents, fellows and medical students in the Movement Disorders clinic on a weekly basis; and teaching in Resident's clinic about once a month. Classroom teaching has consisted of serving as member of the Core Faculty for Harvard Health Sciences Technology Pharmacology course (HST150) and a lecturer for the Harvard Medical School Human Neuroscience and Behavior course. Dr. Standaert serves as Director of the Center for Neurodegeneration and Experimental Therapeutics, Director of the Division of Movement Disorders in the Department of Neurology, Director of the American Parkinson Disease Association (APDA) Advanced Center for Parkinson Research, and Director of the UAB Bachmann-Straus Dystonia and Parkinson’s Disease Center of Excellence. He sees many patients in a weekly clinic and oversees many clinical trials for new treatments in Parkinson’s disease.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.Movement Disorders2019
    2019 Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutationNeurology.  93:510-514. 2019
    2019 Diverse Mechanisms Lead to Common Dysfunction of Striatal Cholinergic Interneurons in Distinct Genetic Mouse Models of DystoniaJournal of Neuroscience.  39:7195-7205. 2019
    2019 Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)Parkinsonism and Related Disorders.  62:201-209. 2019
    2019 Reply to: DUOPA® is an Excellent Alternative Treatment but with Some CaveatsMovement Disorders Clinical Practice.  6:336-337. 2019
    2019 Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseasesNeurology.  92:329-337. 2019
    2019 Widespread tau-specific CD4 T cell reactivity in the general populationJournal of Immunology.  203:84-92. 2019
    2018 Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective studyEpilepsy and Behavior.  87:131-136. 2018
    2018 Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's diseaseJournal of Neuroinflammation.  15. 2018
    2018 Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US PractitionersMovement Disorders Clinical Practice.  5:383-393. 2018
    2018 Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's diseaseMovement Disorders.  33:928-936. 2018
    2018 Anti-inflammatory drug use and progressive supranuclear palsyParkinsonism and Related Disorders.  48:89-92. 2018
    2018 Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP studyMovement Disorders.  33:468-472. 2018
    2018 Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson diseaseExperimental Neurology.  300:179-187. 2018
    2018 Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study Pongkiat Kankirawatana, Dr Rani Singh, Professor David G Standaert, Dr Yuliang Liu, Dr Leon Dure, Dr Jennifer DeWollfe, Professor Gary Cutter, Dr Tyler Gaston, Dr Ashley Thomas, Professor E. Martina Bebin, Dr. Lawrence Ver HoefEpilepsy and Behavior.  (in press). 2018
    2018 Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.npj Parkinson's Disease.  4:4. 2018
    2017 Genetic influences on cognition in progressive supranuclear palsyMovement Disorders.  32:1764-1771. 2017
    2017 Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's DiseaseMovement Disorders Clinical Practice.  4:829-837. 2017
    2017 What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's diseaseMovement Disorders.  32:1341-1342. 2017
    2017 Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking PalsyMovement Disorders.  32:1264-1310. 2017
    2017 Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystoniaExperimental Neurology.  295:162-175. 2017
    2017 Evaluation of AZD1446 as a therapeutic in DYT1 dystoniaFrontiers in Systems Neuroscience.  11. 2017
    2017 Dysregulation of BET proteins in levodopa-induced dyskinesiaNeurobiology of Disease.  102:125-132. 2017
    2017 The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's diseaseBrain Stimulation.  10:651-656. 2017
    2017 An individualized coaching program for patients with acute ischemic stroke: Feasibility studyClinical Neurology and Neurosurgery.  154:89-93. 2017
    2017 Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trialsMovement Disorders.  32:319-324. 2017
    2017 Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indicationsEuropean Polymer Journal.  88:524-552. 2017
    2017 Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's DiseaseMovement Disorders Clinical Practice.  4:183-190. 2017
    2017 Understanding falls in progressive supranuclear palsyParkinsonism and Related Disorders.  35:75-81. 2017
    2017 Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.npj Parkinson's Disease.  3:10. 2017
    2017 The role of stress as a risk factor for progressive supranuclear palsyJournal of Parkinson's Disease.  7:377-383. 2017
    2016 Cholinergic regulation of striatal dopamine release: New light in dark basementsMovement Disorders.  31:1796. 2016
    2016 Glucocerebrosidase, Parkinson disease, and the “senses and intellect”Annals of Neurology.  80:660-661. 2016
    2016 CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.Neurology, Neuroimmunology and Neuroinflammation.  3:e266. 2016
    2016 How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Journal of Neurochemistry.  131-155. 2016
    2016 SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's diseaseMovement Disorders.  31:1479. 2016
    2016 Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's diseaseMovement Disorders.  31:1543-1550. 2016
    2016 Dynamic DNA methylation regulates levodopa-induced DyskinesiaJournal of Neuroscience.  36:6514-6524. 2016
    2016 Biomarkers in Parkinson's disease: From pathophysiology to early diagnosisMovement Disorders.  31:769-770. 2016
    2016 The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary MicrogliaJournal of Neuroimmune Pharmacology.  11:231-237. 2016
    2016 Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegenerationJournal of Neuroscience.  36:5144-5159. 2016
    2016 Environmental and occupational risk factors for progressive supranuclear palsy: Case-control studyMovement Disorders.  31:644-652. 2016
    2016 MicroRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson diseaseJournal of Neuroscience.  36:2383-2390. 2016
    2016 Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor AnalysisMovement Disorders Clinical Practice.  3:65-67. 2016
    2016 Invisible KillersMovement Disorders.  31:44-44. 2016
    2015 ID: 163Cytokine.  76:64-64. 2015
    2015 Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson diseasePLoS ONE.  10. 2015
    2015 Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control studyMovement Disorders.  30:1371-1381. 2015
    2015 Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal GelMovement Disorders.  30:1435-1436. 2015
    2015 Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label resultsMovement Disorders.  30:500-509. 2015
    2015 Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystoniaProgress in Neurobiology.  127-128:91-107. 2015
    2015 Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseaseMovement Disorders.  30:919-927. 2015
    2015 Direct measurement of the Hypercholinergic state in a mouse model of DYT1 DystoniaFrontiers in Neurology.  6. 2015
    2015 Role of α-synuclein in inducing innate and adaptive immunity in Parkinson diseaseJournal of Parkinson's Disease.  5:1-19. 2015
    2014 Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapyViruses.  6:3293-3310. 2014
    2014 Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodentsJournal of Comparative Neurology.  522:2465-2480. 2014
    2014 Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's diseaseJournal of applied physiology: respiratory, environmental and exercise physiology.  116:582-592. 2014
    2014 Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: A randomised, controlled, double-blind, double-dummy studyLancet Neurology.  13:141-149. 2014
    2014 A Full-Brain, Bootstrapped Analysis of Diffusion Tensor Imaging Robustly Differentiates Parkinson Disease from Healthy ControlsNeuroinformatics.  13:7-18. 2014
    2014 Monocytes and Parkinson's disease: Invaders from outside?Movement Disorders.  29:1242. 2014
    2014 Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegenerationMovement Disorders.  29:306-306. 2014
    2014 Scientific perspectivesMovement Disorders.  29:1230. 2014
    2013 LRRK2 secretion in exosomes is regulated by 14-3-3Human Molecular Genetics.  22:4988-5000. 2013
    2013 Metabolomics and the search for biomarkers in Parkinson's diseaseMovement Disorders.  28:1620-1621. 2013
    2013 Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefitMovement Disorders.  28:1675-1682. 2013
    2013 MHCII is required for α-Synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegenerationJournal of Neuroscience.  33:9592-9600. 2013
    2013 Removing the blinkers: Moving beyond striatal dopamine in Parkinson's diseaseJournal of Neurochemistry.  125:639-641. 2013
    2013 Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsParkinsonism and Related Disorders.  19:339-345. 2013
    2013 Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated MicePLoS ONE.  8. 2013
    2012 CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's diseaseJournal of Neuroimmune Pharmacology.  7:927-938. 2012
    2012 The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microgliaJournal of Neuroinflammation.  9. 2012
    2012 Evaluation of TorsinA as a Target for Parkinson Disease Therapy in Mouse ModelsPLoS ONE.  7. 2012
    2012 Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinANeurobiology of Disease.  47:416-427. 2012
    2012 Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystoniaJournal of Neuroscience.  32:11991-12004. 2012
    2012 Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystoniaPLoS ONE.  7. 2012
    2012 LRRK2 inhibition attenuates microglial inflammatory responsesJournal of Neuroscience.  32:1602-1611. 2012
    2012 Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's diseaseParkinsonism and Related Disorders.  18:63-68. 2012
    2011 The Parkinson Progression Marker Initiative (PPMI)Progress in Neurobiology.  95:629-635. 2011
    2011 Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout micePLoS ONE.  6. 2011
    2011 Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystoniaPLoS ONE.  6. 2011
    2011 Update on the pathology of dystoniaNeurobiology of Disease.  42:148-151. 2011
    2011 Altered dendritic morphology of Purkinje cells in DYT1 δGAG knock-in and Purkinje cell-specific DYT1 conditional knockout micePLoS ONE.  6. 2011
    2011 A neuroprotective role for angiogenin in models of Parkinson's diseaseJournal of Neurochemistry.  116:334-341. 2011
    2011 Parkinson's disease, primates, and gene therapy: Vive la différence?Movement Disorders.  26:2-3. 2011
    2010 Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsPLoS ONE.  5. 2010
    2010 Transduction of brain dopamine neurons by adenoviral vectors is modulated by car expression: Rationale for tropism modified vectors in PD gene therapyPLoS ONE.  5:1-9. 2010
    2010 Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's diseaseMolecular Neurodegeneration.  5. 2010
    2010 Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystoniaNeurobiology of Disease.  38:434-445. 2010
    2010 Target validation: The Parkinson disease perspectiveDisease Models & Mechanisms.  3:259-262. 2010
    2010 Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivoJournal of Neurochemistry.  113:228-235. 2010
    2010 VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's diseaseNeurobiology of Disease.  37:330-338. 2010
    2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's diseaseCell Death and Disease.  1. 2010
    2009 O.045 Mechanisms of dystoniaParkinsonism and Related Disorders.  15:S12-S12. 2009
    2009 Monitoring motor fluctuations in patients with parkinsons disease using wearable sensorsIEEE Transactions on Information Technology in Biomedicine.  13:864-873. 2009
    2009 Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegenerationPLoS ONE.  4. 2009
    2009 Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: Role of endogenous acetylcholineBrain.  132:2336-2349. 2009
    2009 Targets for neuroprotection in Parkinson's diseaseBBA - Molecular Basis of Disease.  1792:676-687. 2009
    2009 Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystoniaNeurobiology of Disease.  34:133-145. 2009
    2009 Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapyProceedings of the National Academy of Sciences.  106:2892-2896. 2009
    2009 Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: A cross-sectional studyNeuroepidemiology.  33:329-334. 2009
    2008 Biochemical fractionation of brain tissue for studies of receptor distribution and traffickingCurrent protocols in neuroscience / editorial board, Jacqueline N. Crawley ... [et al.]2008
    2008 Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of parkinson diseaseJournal of Neuropathology and Experimental Neurology.  67:1149-1158. 2008
    2008 Using wearable sensors to predict the severity of symptoms and motor complications in late stage Parkinson's Disease.Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  3686-3689. 2008
    2008 Striatal histone modifications in models of levodopa-induced dyskinesiaJournal of Neurochemistry.  106:486-494. 2008
    2008 Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonismEuropean Journal of Neuroscience.  27:1647-1658. 2008
    2008 The pathophysiological basis of dystoniasNature Reviews Neuroscience.  9:222-234. 2008
    2008 Transcriptional dysregulation in a transgenic model of Parkinson diseaseNeurobiology of Disease.  29:515-528. 2008
    2008 Design of clinical trials of gene therapy in Parkinson diseaseExperimental Neurology.  209:41-47. 2008
    2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Molecular Brain.  1:17. 2008
    2008 Processing wearable sensor data to optimize deep-brain stimulationIEEE Pervasive Computing.  7:56-61. 2008
    2007 Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitroBiochemical and Biophysical Research Communications.  363:846-851. 2007
    2007 Dopamine release is impaired in a mouse model of DYT1 dystoniaJournal of Neurochemistry.  102:783-788. 2007
    2007 Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro modelsBiochemical and Biophysical Research Communications.  357:596-602. 2007
    2007 Effects of gender on nigral gene expression and parkinson diseaseNeurobiology of Disease.  26:606-614. 2007
    2007 Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigraJournal of Neurochemistry.  100:1449-1457. 2007
    2007 Molecular markers of early Parkinson's disease based on gene expression in bloodProceedings of the National Academy of Sciences.  104:955-960. 2007
    2006 Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystoniaNeurobiology of Disease.  24:318-325. 2006
    2006 No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brainActa Neuropathologica.  112:439-449. 2006
    2006 Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit traffickingJournal of Neuroscience.  26:4690-4700. 2006
    2006 Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouseEuropean Journal of Neuroscience.  23:3171-3175. 2006
    2005 Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendrogliaJournal of Neural Transmission.  112:1613-1624. 2005
    2005 Alpha-synuclein and chaperones in dementia with Lewy bodiesJournal of Neuropathology and Experimental Neurology.  64:1058-1066. 2005
    2005 Somatic mitochondrial DNA mutations in single neurons and gliaNeurobiology of Aging.  26:1343-1355. 2005
    2005 Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutationJournal of Neuroscience.  25:5351-5355. 2005
    2005 Applications of laser capture microdissection in the study of neurodegenerative diseaseArchives of Neurology -Chigago-.  62:203-205. 2005
    2005 Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1Human Molecular Genetics.  14:179-189. 2005
    2005 Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseNeuropharmacology.  48:503-516. 2005
    2005 Pacemaker-induced tachycardia caused by inappropriate response to parkinsonian tremorNeurology.  65:1676-1677. 2005
    2004 Levodopa and the progression of parkinson’s diseaseNew England Journal of Medicine.  351:2498-2508. 2004
    2004 Data mining techniques to detect motor fluctuations in Parkinson's diseaseAnnual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings.  26 VII:4766-4769. 2004
    2004 NMDA-R1 antisense oligodeoxynucleotides modify formalin-induced nociception and spinal c-Fos expression in rat spinal cordPharmacology Biochemistry and Behavior.  79:183-188. 2004
    2004 L-type Ca2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatmentJournal of Neuroscience.  24:7464-7476. 2004
    2004 Neuroprotective strategies for Parkinson's diseaseCurrent Neuropharmacology.  2:309-322. 2004
    2004 Rationale for and use of NMDA receptor antagonists in Parkinson's diseasePharmacology and Therapeutics.  102:155-174. 2004
    2004 Changes in the expression of the NR2B subunit during aging in macaque monkeysNeurobiology of Aging.  25:201-208. 2004
    2004 Dopamine D1-Dependent Trafficking of Striatal N-Methyl-D-aspartate Glutamate Receptors Requires Fyn Protein Tyrosine Kinase but Not DARPP-32Molecular Pharmacology.  65:121-129. 2004
    2004 Dopamine transmission in DYT1 dystonia.Advances in Neurology -New York- Raven Press-.  94:53-60. 2004
    2003 Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.Neurology.  61:S30-S31. 2003
    2003 II: A2A receptor modulation for symptomatic therapy in Parkinson's disease: Adenosine A2A receptor modulation of motor systems in PDNeurology.  61. 2003
    2003 Distribution and ultrastructural localization of torsinA immunoreactivity in the human brainBrain Research.  986:12-21. 2003
    2003 Lighting up the senses: FM1-43 loading of sensory cells through nonselective ion channelsJournal of Neuroscience.  23:4054-4065. 2003
    2003 Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: Analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylationNeurobiology of Disease.  14:624-636. 2003
    2003 Predicting the Potential of Wearable TechnologyIEEE Engineering in Medicine and Biology Magazine.  22:23-27. 2003
    2003 Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatumJournal of Neurochemistry.  85:935-943. 2003
    2003 TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletionNeurobiology of Disease.  12:11-24. 2003
    2003 Wearable technology's applications in Parkinson's disease.IEEE Engineering in Medicine and Biology Magazine.  22:25-26. 2003
    2002 Identification of nitric oxide synthase neurons for laser capture microdissection and mRNA quantificationBioTechniques.  33:1274-1283. 2002
    2002 Dopamine transmission in DYT1 dystonia: A biochemical and autoradiographical studyNeurology.  59:445-448. 2002
    2002 Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neuronsNeuropharmacology.  43:161-173. 2002
    2002 Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's diseaseScience.  296:2238-2243. 2002
    2002 Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) ratBrain Research.  101:132-135. 2002
    2002 Expression and activity of antioxidants in the brain in progressive supranuclear palsyBrain Research.  930:170-181. 2002
    2002 Inherited movement disordersNeurologic Clinics.  20:759-778. 2002
    2001 Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membraneJournal of Neuroscience.  21:5546-5558. 2001
    2001 Dystonia and its disordersNeurologic Clinics.  19:681-705. 2001
    2001 Gene expression profiling in the post-mortem human brain - No cause for dismayJournal of Chemical Neuroanatomy.  22:79-94. 2001
    2000 Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trialJournal of the American Medical Association.  284:1931-1938. 2000
    2000 alpha-actinin-2 in rat striatum: localization and interaction with NMDA glutamate receptor subunits.Brain Research.  79:77-87. 2000
    2000 α-Actinin-2 in rat striatum: Localization and interaction with NMDA glutamate receptor subunitsBrain Research.  79:77-87. 2000
    2000 Localization of dopaminergic markers in the human subthalamic nucleusJournal of Comparative Neurology.  421:247-255. 2000
    2000 Localization of dopaminergic markers in the human subthalamic nucleusJournal of Comparative Neurology.  421:247-255. 2000
    2000 Research goals in progressive supranuclear palsyMovement Disorders.  15:446-458. 2000
    2000 Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatumJournal of Comparative Neurology.  419:407-421. 2000
    2000 Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptorsNeuroscience.  97:195-204. 2000
    2000 Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's diseaseMolecular Pharmacology.  57:342-352. 2000
    2000 Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairmentJournal of Neurochemistry.  74:878-881. 2000
    2000 Research goals in progressive supranuclear palsyMovement Disorders.  15:446-458. 2000
    1999 Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neuronsJournal of Comparative Neurology.  415:204-217. 1999
    1999 Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neuronsJournal of Comparative Neurology.  415:204-217. 1999
    1999 Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal gangliaJournal of Comparative Neurology.  415:266-284. 1999
    1999 Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal gangliaJournal of Comparative Neurology.  415:266-284. 1999
    1999 Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brainAnnals of Neurology.  46:761-769. 1999
    1999 A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in miceJournal of Neuroscience.  19:9192-9200. 1999
    1999 Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brainAnnals of Neurology.  46:761-769. 1999
    1999 Association of AMPA receptors with a subset of glutamate receptor- interacting protein in vivoJournal of Neuroscience.  19:6528-6537. 1999
    1999 Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsyJournal of Neurochemistry.  73:881-884. 1999
    1999 Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal gangliaJournal of Comparative Neurology.  407:33-46. 1999
    1999 Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal gangliaJournal of Comparative Neurology.  407:33-46. 1999
    1999 Immunohistochemical localization of N-methyl-D-aspartate and α-amino- 3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the ratNeuroscience.  89:209-220. 1999
    1999 Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the ratBrain Research.  64:11-23. 1999
    1999 Distribution of group III mGluRs in rat basal ganglia with subtype-specific antibodiesAnnals of the New York Academy of Sciences.  868:531-534. 1999
    1999 NMDA receptors and nitric oxide synthaseMolecular Psychiatry.  4:13-14. 1999
    1999 Neuroprotective therapiesMedical Clinics of North America.  83:509-523. 1999
    1998 The human N-methyl-D-aspartate receptor 2C subunit: Genomic analysis, distribution in human brain, and functional expressionJournal of Neurochemistry.  71:1953-1968. 1998
    1998 Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probesBrain Research.  3:22-32. 1998
    1998 Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the ratNeuroscience.  86:783-798. 1998
    1998 Expression of the early onset torsion dystonia gene (DYT1) in human brainAnnals of Neurology.  43:669-673. 1998
    1998 Differential localization of the mRNAs for the pertussis toxin insensitive G-protein alpha sub-units G(q), G11, and G(z) in the rat brain, and regulation of their expression after striatal deafferentationBrain Research.  54:298-310. 1998
    1998 NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical, and hippocampal nitric oxide synthase neuronsJournal of Neuroscience.  18:1725-1734. 1998
    1998 Expression of N-Methyl-D-Aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neuronsJournal of Comparative Neurology.  390:91-101. 1998
    1998 Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidusJournal of Comparative Neurology.  390:63-74. 1998
    1998 Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neuronsJournal of Comparative Neurology.  390:91-101. 1998
    1998 Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortexJournal of Comparative Neurology.  390:75-90. 1998
    1998 Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidusJournal of Comparative Neurology.  390:63-74. 1998
    1998 Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal gangliaJournal of Comparative Neurology.  390:5-19. 1998
    1998 Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal gangliaJournal of Comparative Neurology.  390:5-19. 1998
    1998 Treating Parkinson's disease.Health News -Waltham then Greenwich Ct-.  4:1-2. 1998
    1997 N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivoNeuroscience Letters.  236:91-94. 1997
    1997 Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brainBrain Research.  768:215-223. 1997
    1997 Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampusBrain Research.  48:259-269. 1997
    1997 Cloning and stable expression of the mGluR1b subtype of human metabotropic receptors and pharmacological comparison with the mGluR5a subtypeNeuropharmacology.  36:917-931. 1997
    1997 Erratum: Malondialdehyde immunohistochemistry in Parkinson's disease (Movement Disorders (1996) 11 (592))Movement Disorders.  12:131. 1997
    1997 Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellumNeurobiology of Disease.  4:35-46. 1997
    1997 Huntingtin immunoreactivity in the rat neostriatum: Differential accumulation in projection and interneuronsExperimental Neurology.  144:239-247. 1997
    1996 Immunohistochemical localization of metabotropic glutamate receptors (mGluRs) in the rat basal gangliaNeuropharmacology.  35:A30-A30. 1996
    1996 Metabotropic glutamate receptors modulate striatal quinolinic acid toxicityNeuropharmacology.  35:A22-A22. 1996
    1996 Expression of N-methyl-D-aspartate glutamate receptor subunits in the prefrontal cortex of the ratNeuroscience.  73:417-427. 1996
    1996 Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampusBrain Research.  42:89-102. 1996
    1996 Glutamate receptor genes in Parkinson's disease.Advances in Neurology -New York- Raven Press-.  69:79-86. 1996
    1996 Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulationJournal of Pharmacology and Experimental Therapeutics.  276:342-352. 1996
    1995 Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesionsNeuroscience Letters.  202:109-112. 1995
    1995 NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum.Journal of Neuroscience.  15:5297-5307. 1995
    1995 DNA fragmentation and immediate early gene expression in rat striatum following quinolinic acid administrationExperimental Neurology.  133:207-214. 1995
    1995 Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neuronsJournal of Comparative Neurology.  354:241-252. 1995
    1995 NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatumJournal of Neuroscience.  15:5297-5307. 1995
    1994 Glutamate receptor expression in rat striatum: Effect of deafferentationBrain Research.  647:209-219. 1994
    1994 Metabotropic glutamate receptor mRNA expression in the basal ganglia of the ratJournal of Neuroscience.  14:3005-3018. 1994
    1994 Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat.Journal of Neuroscience.  14:3005-3018. 1994
    1994 Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the ratBrain Research.  21:283-292. 1994
    1994 Metabotropic glutamate receptors are differentially regulated during developmentNeuroscience.  61:481-495. 1994
    1994 Organization of N‐methyl‐D‐aspartate glutamate receptor gene expression in the basal ganglia of the ratJournal of Comparative Neurology.  343:1-16. 1994
    1993 Alternatively spliced isoforms of the NMDAR1 glutamate receptor subunit: Differential expression in the basal ganglia of the ratNeuroscience Letters.  152:161-164. 1993
    1993 Update on the management of Parkinson's diseaseMedical Clinics of North America.  77:169-183. 1993
    1992 Magnetic Resonance Angiography in the Evaluation of Dural Carotid-Cavernous FistulasJournal of Neuroimaging.  2:208-211. 1992
    1991 Meningovascular syphilis with a gumma of the midbrainJournal of clinical neuro-ophthalmology.  11:139-143. 1991
    1991 Molecular features of hypothalamic plaques in Alzheimer's diseaseAmerican Journal of Pathology.  139:681-691. 1991
    1988 Expression of the gene for preproatriopeptin in the central nervous system of the rat.Brain Research.  464:7-13. 1988
    1988 Expression of the gene for preproatriopeptin in the central nervous system of the ratBrain Research.  4:7-13. 1988
    1988 Origin of the atriopeptin-like immunoreactive innervation of the paraventricular nucleus of the hypothalamusJournal of Neuroscience.  8:1940-1950. 1988
    1987 Inhibition of the firing of vasopressin neurons by atriopeptinNature.  329:151-153. 1987
    1987 Ventricular atriopeptin: Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasoneHypertension.  9:485-491. 1987
    1986 Colocalization of atriopeptin-like immunoreactivity with choline acetyltransferase-and substance P-like immunoreactivity in the pedunculopontine and laterodorsal tegmental nuclei in the ratBrain Research.  382:163-168. 1986
    1986 Opioid peptide immunoreactivity in spinal and trigeminal dorsal horn neurons projecting to the parabranchial nucleus in the ratJournal of Neuroscience.  6:1220-1226. 1986
    1986 Organization of atriopeptin‐like immunoreactive neurons in the central nervous system of the ratJournal of Comparative Neurology.  253:315-341. 1986
    1985 Atriopeptin immunoreactive neurons in cardiovascular regulatory areas of the brain in the ratFederation proceedings.  44. 1985
    1985 Atriopeptin-immunoreactive neurons in the brain: Presence in cardiovascular regulatory areasScience.  227:1047-1049. 1985
    1985 Atriopeptin: potent hormone and potential neuromediatorTrends in Neurosciences.  8:509-511. 1985
    1985 Atriopeptins as cardiac hormonesHypertension.  7:469-482. 1985
    1985 Spinal and trigeminal dorsal horn projections to the parabrachial nucleus in the ratJournal of Comparative Neurology.  240:153-160. 1985
    1984 Proctolin in the lobster: the distribution, release, and chemical characterization of a likely neurohormone.Journal of Neuroscience.  4:1300-1311. 1984
    1977 Beneficial effect of fluorocarbon emulsion media on the function of neuromuscular preparations in vitroJournal of General Physiology.  69:655-666. 1977

    Book

    Year Title Altmetric
    2011 Movement Disorders, Third Edition 2011

    Chapter

    Year Title Altmetric
    2016 Pharmacology of dopaminergic neurotransmission 2016
    2014 Basal Ganglia Disorders 2014
    2013 Basal Ganglia Disorders.  1-39. 2013
    2012 Pharmacology of dopaminergic neurotransmission.  440-480. 2012
    2009 Torsion Dystonia.  1029-1034. 2009
    2007 Sex Differences in Parkinson's Disease 2007
    2005 DYT1 transgenic mouse.  287-292. 2005
    2005 Neurogenetics of dystonia and paroxysmal dyskinesias.  403-426. 2005

    Research Overview

  • My laboratory is working on understanding both the root causes of Parkinson disease (PD) as well as the origin of the disabling symptoms that appear after long term treatment of the disease. The lab has a strong translational orientation – our goal is to accelerate the delivery of new therapies for Parkinson disease to the patients who desperately need them. A primary focus of the laboratory is understanding the role of the protein alpha-synuclein in PD pathophysiology, and searching for novel approaches for protecting the brain from the effects of excess alpha-synuclein. We use a variety of cellular and rodent models, and are exploring the effects of several chaperone molecules, including those derived from open-ended screens in simple non-mammalian systems. A related interest is the role of neuroinflammation in PD. In human PD, there is a marked brain inflammatory response. Recent work in the Standaert lab using mouse models has led to the idea that this inflammation may be triggered directly by the presence of excess alpha-synuclein. The response involves both microglia as well as the adaptive immune system, and both components may be targets of therapies to prevent or retard the disease. We are also exploring the effect of levodopa on brain function in PD. Levodopa remains the most effective existing treatment, but long-term therapy leads to many unwanted side effects (“wearing off” and “dyskinesia”). The Standaert lab has shown that many of the effects result from abnormal synaptic plasticity in the basal ganglia, and mislocalization of glutamate receptor systems. Recently, we found that the mechanisms responsible for the maintenance of this aberrant plasticity are likely the result of levodopa-induced epigenetic modifications.
  • Principal Investigator On

  • Private Grant  awarded by ABBVIE INC 2019 - 2024
  • The Parkinson's Progression Marker's Initiative (PPMI)  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2010 - 2023
  • Contribution of the Interaction Between Synuclein and Tau in the Pathophysiology of Dementia with Lewy Bodies  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Core A: Administrative Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: Role of Innate Immune Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Project 3: LRRK2 Mediated Macrophage Responses in PD  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Interactions of Gut Microbiome, Genetic Susceptibility and Environmental Factors in Parkinson's Disease  awarded by DOD - Department of Defense 2018 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • UAB Training Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • UAB Cannabidiol Program  awarded by ALABAMA DEPARTMENT OF COMMERCE 2014 - 2022
  • The Edmond J. Safra Fellowship in Movement Disorders 2019 Program  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2019 - 2022
  • Border-Associated Macrophages in an Alpha-Synuclein Overabundance Model of Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2021
  • Role of T cells in an Alpha-Synuclein Mediated Mouse Model of Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2021
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • The Role of T Cells in Inflammation-induced Neurodegeneration  awarded by American Parkinson Disease Association 2019 - 2020
  • APDA Advanced Center for Parkinson Disease Research at UAB  awarded by American Parkinson Disease Association 2008 - 2020
  • University of Alabama at Birmingham_The Edumond J. Safra Fellowship in Movement Disorders 2017  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2017 - 2020
  • MJFF Emerging Targets Committee Membership  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2016 - 2020
  • Role of HLA/MHCII in Parkinson's Disease Pathogenesis  awarded by Emory University 2015 - 2020
  • Molecular Etiology of Early Onset Torsion Dystonia  awarded by MASSACHUSETTS GENERAL HOSPITAL 2015 - 2020
  • UAB Neuroscience Core Center - Core B: Molecular Detection and Stereology Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2020
  • The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson Disease Foundation  awarded by National Parkinson Foundation, Inc. 2017 - 2019
  • The Edmond J. Safra Fellowship in Movement Disorders  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2016 - 2019
  • UAB Bachmann-Straus Dystonia and Parkinson's Disease Center of Excellence  awarded by Bachmann-Strauss Dystonia & Parkinson Foundation, Inc 2013 - 2018
  • Genetics of Levodopa Induced Dyskinesia  awarded by 23ANDME, INC. 2017 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease - Core A: Administrative Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease - Project 3: Role of Myeloid Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Clinician-Input Study: How the Fox Insight Mobile Application can Influence Treatment and Care (CIS-PD)  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2016 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by ACERTA PHARMA B.V. 2014 - 2016
  • Genetic Susceptibility and Epigenetic Modulation in Levodopa Induced Dyskinesia  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2016
  • Evaluation of the Effects of a Novel Nicotinic Agonist, AZD1446, on Neurochemical and Electrophysiologic Endpoints in DYT1 Mouse Models.  awarded by Dystonia Medical Research Foundation 2015 - 2016
  • Cholinergic and Dopaminergic Mechanisms in Mouse Models of Dystonia  awarded by Mount Sinai School of Medicine 2015 - 2016
  • Private Grant  awarded by SANGAMO BIOSCIENCES, INC. 2013 - 2016
  • Role of MicroRNAs in Modulating Inflammation in Alpha-Syn Mediated Models of PD  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2016
  • Private Grant  awarded by ABBVIE INC 2012 - 2016
  • Validation of the Class II MHC Transactivator (CIITA) in Models of PD  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2014 - 2016
  • Private Grant  awarded by ABBVIE INC 2010 - 2015
  • Molecular Etiology of Early Onset Torsin Dystonia  awarded by MASSACHUSETTS GENERAL HOSPITAL 2009 - 2015
  • UAB PD Neuroprotection Clinical Trial Center  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2014
  • Role of MHC II Proteins in Parkinson's Related Inflammation  awarded by RJG FOUNDATION 2011 - 2014
  • Role of Complement in Alpha-Synuclein Based Models of Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2014
  • Private Grant  awarded by Solvay Pharmaceuticals, Inc. 2010 - 2014
  • Private Grant  awarded by ABBOTT LABORATORIES 2009 - 2014
  • Genetic and Enviromental Risk Factors for Progressive Supranuclear Palsy (PSP)  awarded by University of Louisville 2006 - 2013
  • A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients with Early Parkinson Disease  awarded by University of Rochester 2009 - 2013
  • Developing an Adenoviral Vector Platform for Selective Gene Delivery to Neurons  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2009 - 2013
  • 2012 HDSA Center of Excellence Grant  awarded by Huntington's Disease Society of America, Inc. 2011 - 2012
  • Private Grant  awarded by ABBOTT LABORATORIES 2008 - 2012
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2011
  • Private Grant  awarded by TEVA NEUROSCIENCE, INC. 2010 - 2011
  • HD Program of Excellence at the University of Alabama at Birmingham  awarded by Huntington's Disease Society of America, Inc. 2011
  • Biomarkers and Immunotherapy for Parkinson's Disease  awarded by UNIVERSITY OF NEBRASKA 2010 - 2011
  • Effects of Coenzyme Q10 in PSP, A Multicenter, Randomized, Placebo-Controlled, Double Blind Study  awarded by LAHEY CLINIC, INC. 2008 - 2011
  • Effects of Selective Inactivation of the DYT1 Gene on Cholinergic Function  awarded by Bachmann-Strauss Dystonia & Parkinson Foundation, Inc 2009 - 2010
  • APDA Advanced Center for Parkinson Disease Research at UAB  awarded by American Parkinson Disease Association 2007 - 2008
  • Investigator On

  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Interactions of Gut Microbiome, Genetic Susceptibility and Environmental Factors in Parkinson's Disease  awarded by DOD - Department of Defense 2018 - 2022
  • Role of Alpha Synuclein in PINK1-linked Parkinson's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Admin Oversight Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Pilot Projects Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Diagnosis of Parkinson's Disease Using Diffusion Tensor Imaging  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2020
  • UAB Neuroscience Core Center  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2020
  • Center for Translational Research on Aging and Mobility - Core B: Pilot Core  awarded by National Institute on Aging/NIH/DHHS 2014 - 2020
  • Center for Translational Research on Aging and Mobility  awarded by National Institute on Aging/NIH/DHHS 2014 - 2019
  • Private Grant  awarded by GW RESEARCH LTD. 2014 - 2018
  • Private Grant  awarded by GW RESEARCH LTD. 2014 - 2018
  • Exosome LRRK2 in Predicting Parkinson Disease Phenotypes  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Private Grant  awarded by AVID RADIOPHARMACEUTICALS 2014 - 2018
  • Striatal Modulation of Epigenetic DNA Demethylation in Reward Learning  awarded by National Institute on Drug Abuse/NIH/DHHS 2016 - 2018
  • Modeling X-Linked Dystonia Parkinsonism Using BAC Transgenesis  awarded by MASSACHUSETTS GENERAL HOSPITAL 2015 - 2018
  • The Role of the JAK/STAT Pathway in Human Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2017 - 2018
  • The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD Patients  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Interdisciplinary Training in Pathobiology and Rehabilitation Medicine  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2012 - 2017
  • LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2016
  • Mechanisms of Frontotemporal Dementia Like Behavior in Progranulin Deficient Mice  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2016
  • Training Program in the Neurobiology of Cognition and Cognitive Disorders  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2016
  • Mechanisms of LRRK2 Mediated Neurotoxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2010 - 2016
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2015 - 2016
  • Fox Investigation for New Discovery of Biomarkers (BioFIND)  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2014 - 2015
  • The Role of Astrocytes in Huntington's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2010 - 2015
  • Collaborative MS Research Center Award  awarded by National Multiple Sclerosis Society 2009 - 2015
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2015
  • Role of Microglial LRRK2 in Inflammation  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2015
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2011 - 2014
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2012 - 2014
  • Role of 14-3-3 Proteins in Alpha-Synuclein-Induced Neurotoxicity  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by ASTRAZENECA AB 2013
  • DMRF Clinical Fellowship Training Program  awarded by Dystonia Medical Research Foundation 2012 - 2013
  • 14-3-3s as Regulators of LRRK2 Toxicity  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2011 - 2013
  • Private Grant  awarded by ALLON THERAPEUTICS 2010 - 2013
  • The Effects of Lower and High Frequency Unilateral STN DBS on Sleep in Parkinson's Disease  awarded by American Sleep Medicine Foundation 2011 - 2012
  • Private Grant  awarded by ADDEX PHARMA SA 2011 - 2012
  • Education And Training

  • Doctor of Medicine, Washington University/St. Louis 1982
  • Jewish Hospital of St. Louis, Internship 1989
  • Jewish Hospital of St. Louis, Internship 1989
  • University of Pennsylvania Hospital, Residency 1992
  • University of Pennsylvania, Residency 1992
  • Massachusetts General Hospital, Postdoctoral Fellowship 1995
  • Full Name

  • David Standaert